CytoCell Logo

Includes FDA-cleared Class II IVD FISH Probe Kits for AML and MDS, along with over 150 ASR FISH probes. Custom FISH probes and ancillary products also available.

Discover more
CytoSure Logo

Featuring the new constitutional NGS platform for cytogenetic research, alongside a broad range of arrays for rare disease and cancer research.

Discover more
SureSeq Logo

Choose from preloaded NGS panels for hematological and solid tumor cancer research or we can help you create your own.

Discover more

Try our handy FISH and NGS product tools

FISH chromosome search

View

Constitutional NGS chromosome search

View

Custom NGS cancer panel builder

View

Featured products

Detect 49 key genes implicated in myeloid disorders

SureSeq Myeloid Plus Workflow

The panel accurately detects SNVs and indels in genes such as CEBPA, JAK2, CALR and MPL, as well as structural variants including FLT3-ITDs and KMT2A-PTDs, and is able to detect low-frequency SNVs and indels with confidence. The figure (right) shows a PTD detection spanning exons 2-8 of the KMT2A gene.

SureSeq Myeloid Plus Workflow Image

New high-quality ASR solid tumor FISH probes

CDKN2A / 3 alpha satellite / 7 alpha satellite / 17 alpha satellite

The CDKN2A Probe covers CDKN2A (P16) gene and flanking regions, and is labeled in gold. The Centromere 17 Probe covers the chromosome 17 centromere (D17Z1) region and is labeled in aqua. The Centromere 3 Probe covers the chromosome 3 centromere (D3Z1) region and is labeled in red. The Centromere 7 Probe covers the chromosome 7 centromere (D7Z1) region and is labeled in green.

CDKN2A / 3 alpha satellite / 7 alpha satellite / 17 alpha satellite Image

The optimal solution for your FH research

CytoSure Comprehensive FH Panel

Familial Hypercholesterolaemia (FH) is a genetic condition which results in a high cholesterol level and subsequently leads to a higher risk of early heart disease. OGT is offering an optimised NGS panel which has selected the most relevant genes and SNPs implicated in FH, for your research needs. The figure (left) shows a double deletion on the LDLR gene, as visualised by Interpret software.

CytoSure Comprehensive FH Panel Image

Featured resources

View more resources

What binds us, makes us.

We believe that collaboration is key to improving patient lives. By sharing our knowledge and expertise, we ensure that we move forward with our customers, bound by a collective commitment to unlocking the future of genetic clinical care. See our story.

See our story of partnership (130 seconds) Image
Play Icon

See our story of partnership (130 seconds)

Latest OGT news

View all OGT News
Group photo of OGT employees at the opening of the new office in Oxford

OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park

07 Feb 2024

Investment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships.

Read
OGT to premiere SureSeq Myeloid MRD panel for AML disease monitoring at AMP Image

OGT to premiere SureSeq Myeloid MRD panel for AML disease monitoring at AMP

13 Nov 2023

New NGS assay delivers exceptional coverage, providing a rapid and highly sensitive means of investigating MRD in AML samples

Read
OGT Intelliseq Partnership

OGT and Intelliseq launch NGS reporting and interpretation for all myeloid malignancy panels

26 Oct 2023

Fueled by cutting-edge clinical and genomic data, partnership provides intuitive and fully customizable reporting capabilities for all conditions

Read
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter